The Center for Biosimilars® recaps the top news for the week of December 31, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 31.
Number 5: A recent study evaluated the safety and efficacy of a single dose of rituximab for the treatment of idiopathic nephrotic syndrome in children.
Number 4: A new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
Number 3: In comments submitted to CMS, the American College of Rheumatology expressed concern that the proposed International Pricing Index may disrupt patient access to care.
Number 2: JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
Number 1: A recent systematic review found that US and European providers are still taking a cautious approach to biosimilars, in part because of a lack of awareness of these medicines.
Finally, last week, our e-newsletter asked which area of biosimilar uptake is the most critical for payers to grapple with.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.